MedTrace Logo

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma

NCT00396682 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-02-04

No results posted yet for this study

Summary

It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.

Conditions

  • Advanced HCC

Interventions

DRUG

Cyclophosphamide

150 - 250 - 350 mg

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Tim F Greten, M.D. · Department of Gastroenterology, Medizinische Hochschule Hannover

  • Tim F Greten, M.D. · Hannover Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00396682 on ClinicalTrials.gov